Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

OBJECTIVE: To verify the hypothesis that in rheumatoid arthritis (RA), tumor necrosis factor alpha (TNFalpha) plays a critical role in regulating leukocyte trafficking and chemokine levels. METHODS: Ten patients with longstanding RA received a single 10 mg/kg infusion of anti-TNFalpha monoclonal ant...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Taylor, P, Peters, A, Paleolog, E, Chapman, P, Elliott, M, McCloskey, R, Feldmann, M, Maini, R
Format:	Journal article
Sprache:	English
Veröffentlicht:	2000

Ähnliche Einträge

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
von: Paleolog, E, et al.
Veröffentlicht: (1998)

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
von: Maini, R, et al.
Veröffentlicht: (1995)

Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade.
von: Davis, D, et al.
Veröffentlicht: (1997)

Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action.
von: Feldmann, M, et al.
Veröffentlicht: (1997)

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.
von: Paleolog, E, et al.
Veröffentlicht: (1996)

Similar effects of pulse corticosteroid and tumor necrosis factor a blockade in rheumatoid arthritis: Reply
von: Taylor, P, et al.
Veröffentlicht: (2001)

TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action.
von: Elliott, M, et al.
Veröffentlicht: (1995)

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
von: Feldmann, M, et al.
Veröffentlicht: (1997)

Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
von: Brennan, F, et al.
Veröffentlicht: (1995)

Effects of treatment of rheumatoid arthritis patients with an antibody against tumour necrosis factor alpha on reticuloendothelial and intrapulmonary granulocyte traffic.
von: Taylor, P, et al.
Veröffentlicht: (1999)

Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus.
von: Maini, R, et al.
Veröffentlicht: (1994)

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
von: Elliott, M, et al.
Veröffentlicht: (1993)

TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.
von: Maini, R, et al.
Veröffentlicht: (1997)

TNFα blockade in rheumatoid arthritis: Rationale, clinical outcomes and mechanisms of action
von: Elliott, M, et al.
Veröffentlicht: (1995)

Cytokine blockade in rheumatoid arthritis.
von: Feldmann, M, et al.
Veröffentlicht: (2001)

Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor alpha therapy in rheumatoid arthritis - Reply
von: Maini, R, et al.
Veröffentlicht: (1998)

Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis.
von: Feldmann, M, et al.
Veröffentlicht: (1994)

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.
von: Elliott, M, et al.
Veröffentlicht: (1994)

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
von: Maini, R, et al.
Veröffentlicht: (1999)

TNF alpha as a therapeutic target in rheumatoid arthritis.
von: Feldmann, M, et al.
Veröffentlicht: (1994)

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis.
von: Chu, C, et al.
Veröffentlicht: (1991)

Targeting TNF alpha for the therapy of rheumatoid arthritis.
von: Maini, R, et al.
Veröffentlicht: (1994)

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
von: Elliot, M, et al.
Veröffentlicht: (2008)

Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures.
von: Schmidt, E, et al.
Veröffentlicht: (2013)

TNF alpha is an effective therapeutic target for rheumatoid arthritis.
von: Feldmann, M, et al.
Veröffentlicht: (1995)

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha.
von: Haworth, C, et al.
Veröffentlicht: (1991)

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.
von: Maini, R, et al.
Veröffentlicht: (1995)

Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
von: Ulfgren, A, et al.
Veröffentlicht: (2000)

TNF alpha--a pivotal role in rheumatoid arthritis?
von: Brennan, F, et al.
Veröffentlicht: (1992)

Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha.
von: Williams, R, et al.
Veröffentlicht: (2000)

Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha.
von: Buchan, G, et al.
Veröffentlicht: (1988)

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha.
von: Deleuran, B, et al.
Veröffentlicht: (1992)

What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
von: Feldmann, M
Veröffentlicht: (1996)

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
von: Feldmann, M, et al.
Veröffentlicht: (2001)

The role of TNF alpha and IL-1 in rheumatoid arthritis.
von: Feldmann, M, et al.
Veröffentlicht: (2001)

Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies.
von: Feldmann, M, et al.
Veröffentlicht: (2002)

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
von: Maini, R, et al.
Veröffentlicht: (1993)

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
von: Elliott, M, et al.
Veröffentlicht: (1994)

Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
von: Feldmann, M, et al.
Veröffentlicht: (1995)

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.
von: Brennan, F, et al.
Veröffentlicht: (1997)